NCT01254526View on ClinicalTrials.gov

Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

April 30, 2013

Conditions
Breast Cancer
Interventions
DRUG

GDC-0980

Oral repeating dose

DRUG

bevacizumab

Intravenous repeating dose

DRUG

paclitaxel

Intravenous repeating dose

Trial Locations (3)

3000

Leuven

37203

Nashville

02115

Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY